Clinical Trial

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Study acronym: CodeBreaK 301
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Protocol Amendment History 3 changes
notable Trial sites expanded: 286 -> 290 locations 2026-06-11
notable Primary completion pushed: 2028-01-31 -> 2028-09-25 2026-06-11
minor Completion pushed: 2031-08-31 -> 2032-04-25 2026-06-11
Trial Details
NCT Number NCT06252649
Lead Sponsor Amgen
Conditions Metastatic Colorectal Cancer
Enrollment 450 participants
Start Date 2024-07-17
Primary Completion 2028-09-25 (estimated)
Study Completion 2032-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-16